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Background and aims: Epithelial-to-mesenchymal transition (EMT) and the reverse mesenchymal-to-epithelial
transition (MET) are manifestations of cellular plasticity that imply a dynamic and profound gene expression
reprogramming.While amajor epigenetic code controlling the coordinated regulation of a whole transcriptional
profile is guaranteed by DNAmethylation, DNA methyltransferase (DNMT) activities in EMT/MET dynamics are
still largely unexplored.
Here, we investigated the molecular mechanisms directly linking HNF4α, the master effector of MET, to the
regulation of both de novo of DNMT 3A and 3B.
Methods: Correlation among EMT/MET markers, microRNA29 and DNMT3s expression was evaluated by
RT-qPCR, Western blotting and immunocytochemical analysis. Functional roles of microRNAs and DNMT3s
were tested by anti-miRs, microRNA precursors and chemical inhibitors. ChIP was utilized for investigating
HNF4α DNA binding activity.
Results: HNF4α silencing was sufficient to induce positive modulation of DNMT3B, in in vitro differentiated
hepatocytes as well as in vivo hepatocyte-specific Hnf4α knockout mice, and DNMT3A, in vitro, but not
DNMT1. In exploring the molecular mechanisms underlying these observations, evidence have been gathered
for (i) the inverse correlation between DNMT3 levels and the expression of their regulators miR-29a and miR-
29b and (ii) the role of HNF4α as a direct regulator of miR-29a-b transcription. Notably, during TGFβ-induced
EMT, DNMT3s' pivotal function has been proved, thus suggesting the need for the repression of these DNMTs
in the maintenance of a differentiated phenotype.
Conclusions: HNF4αmaintains hepatocyte identity by regulating miR-29a and -29b expression, which in turn
control epigenetic modifications by limiting DNMT3A and DNMT3B levels.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).; DNMT, DNAmethyltransferase; EMT, epithelial tomesenchymal transition;MET,mesenchymal to epithelial transition; TGFβ,
actor4alpha;qPCR,real-timepolymerasechainreaction;RT–qPCR, reverse-transcriptionandreal-timepolymerasechainreaction
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Table A.1
List and sequences of primers.
Target gene (Mus musculus) Primer sequences (5′–3′)
Snail Fw CCACTGCAACCGTGCTTTT
Rev CACATCCGAGTGGGTTTGG
HNF4α Fw TCTTCTTTGATCCAGATGCC
Rev GGTCGTTGATGTAATCCTCC
DNMT3A Fw CTGTCCCATCCAGGCAGT
Rev CTTAGCGGTGTCTTGGAA
DNMT3B Fw GCAAGACCTTCTCCAGCA
Rev CTTGTTGGGTTTGAGGCCCT
DNMT1 Fw CCCAAAAGAAGGATCCTG
Rev AGTTTGATGTCTGCCTCG
Occludin Fw ACCTGATGAATTCAAACCCA
Rev GTGAAGAATTTCATCTTCCGG
Mmp9 Fw CTTGAAGTCTCAGAAGGTGG
Rev GGCTTTGTCTTGGTACTGG
E-cadherin Fw CTACTGTTTCTACGGAGGAG
Rev CTCAAATCAAAGTCCTGGTC
Vimentin Fw AGCAGTATGAAAGCGTGGCT
Rev CTCCAGGGACTCGTTAGTGC
β-actin Fw ACCACACCTTCTACAATGAG
Rev AGGTCTCAAACATGATCTGG
U6 Fw GCTTCGGCAGCACATATACT
Rev GAATTTGCGTGTCATCCTTG
mmu-miR-29a Fw T*GC*C*ATCTGAAAT (*LNA)
Rev AACTGCGGATTATCGAACTAT
mmu-miR-29b Fw T*AG*CA*CCATTTGAAA (*LNA)
Rev TTTGAACATAGATTGGGCTC
18S Fw ACGACCCATTCGAACGTCTG
Rev GCACGGCGACTACCATCG
L34 Fw GGAGCCCCATCCAGACTC
Rev CGCTGGATATGGCTTTCCTA
Snord66 Fw G*C*GTGCCACGTGT (*LNA)
Rev CCACAGCCATAGTCAGTACAAGGTCCTC
920 C. Cicchini et al. / Biochimica et Biophysica Acta 1849 (2015) 919–9291. Introduction
The execution of epithelial cells' specific functions, guaranteed by
differentiated phenotypes, includes the capacity to respond to environ-
mental cues that trigger mesenchymal transdifferentiation. This
pleiotropic process known as epithelial-to-mesenchymal transition
(EMT), manifestation of plasticity by a deep and dynamic gene expres-
sion reprogramming, is often followed by the reverse mesenchymal-to-
epithelial transition (MET), occurring in a secondary site and in a
different cellular environment. EMT/MET dynamics occur in both
physiological phenomena, such as organogenesis, development,
wound healing and regeneration, and pathological conditions. The aber-
rant acquisition of mesenchymal characteristics by epithelial cells, with
the loss of apical-basal polarity and the enhanced migratory capacity,
characterizes fibrosis, tumor progression and metastasis [1].
Epigenetic mechanisms are conceivably mandatory in allowing the
execution of such a deep and dynamic cellular reprogramming that
involves the coordinated regulation of a whole transcriptional profile.
A major epigenetic code controlling gene expression is guaranteed
by DNA methylation orchestrated by DNA methyltransferases 1
(DNMT1) and 3 (DNMT3A and DNMT3B) [2]. Current knowledge
indicates that while DNMT1 is primarily involved in the maintenance
of an established DNA methylation pattern [3], the DNMT3s possess
an efficient de novo methylation activity necessary to determine new
methylation patterns required during development [4]. The aberrant
modification of epigenetic marks also characterizes various malignan-
cies and, in particular, the levels of DNMTs are elevated in several
cancers including hepatocarcinoma (HCC) [5,6]. Specifically in HCC,
changes in cytosine methylation were suggested as possible molecular
markers for tumor progression while treating HCC cells with the
DNMT inhibitor decitabine reduced invasiveness [7,8].DNA methylation in EMT/MET dynamics is still largely unexplored
and evidence are mainly limited to the inverse correlation found
between DNA methylation and transcription levels of EMT/MET key
markers [9–11] and to thewhole genome EMT-associated DNAmethyl-
ation changes [12]. Moreover, the molecular mechanisms directly
linking master effectors of EMT/MET to DNA methylation by DNMTs
are still not unveiled.
Wide evidence demonstrated that the orphan nuclear receptor he-
patocyte nuclear factor 4-α (HNF4α), master regulator of hepatocyte
differentiation and hepatic epithelium formation [13,14], also acts as a
master regulator of MET (for review [15]). Notably, a role for HNF4α
as a direct repressor of master EMT regulators and mesenchymal
genes was recently unveiled, thus providing evidence for its pivotal
function for both the regulation of the dynamic process of MET and
the maintenance of a stable epithelial phenotype [16].
Here, the HNF4α role in the maintenance of hepatocyte epithelial
identity is linked to the epigenetic modifications featured by de novo
DNMT3A and DNMT3B. HNF4α silencing in differentiated hepatocytes
was, in fact, found sufficient to induce both DNMT3A and DNMT3B
positive modulation in vitro and DNMT3B in vivo, while DNMT1 levels
were unchanged. Exploring the molecular mechanisms underlying
these observations, evidence for (i) the inverse correlation among the
levels of DNMT3A and DNMT3B and the expression of miR-29a and
miR-29b, targeting their transcripts [17] and (ii) the role for HNF4α as
direct regulator of these microRNA transcription have been gathered.
Notably, during the transforming growth factor β (TGFβ)-induced
EMT of differentiated hepatocytes, DNMT3 up-regulation was found to
occur and its function in this process suggested.
2. Materials and methods
2.1. Cell culture conditions
Untransformed differentiated hepatocytes [18] were grown in RPMI
1640 with 10% FBS (GIBCO® Life Technology, Monza, Italy), 50 ng/ml
EGF, 30 ng/ml IGF II (PeproTech Inc., Rocky Hill, NJ, USA), 10 μg/ml
insulin (Roche, Mannheim, Germany) and antibiotics, on collagen I
(GIBCO® Life Technology, Monza, Italy) coated dishes. When indicated,
cells were treated with 5 μMTGFβ1 for 24 h (PeproTech Inc., Rocky Hill,
NJ, USA), according to [19], and/or with 4 μM DNA-methyltransferases
inhibitor 5-Azacytidine (5-Aza; Sigma-aldrich, Sant Louis, MO, USA).
2.2. Animal model and treatment
Conditional temporal Hnf4aF/F;AlbERT2cremice used in this study were
previously described (PMID: 22241473). In brief, Hnf4aF/F mice were
crossed with SA+/Cre-ERT2 mice expressing a tamoxifen-inducible,
hepatocyte-specific Cre recombinase (PMID: 15282742 & 21725089).
Cre recombinase expression and subsequent gene knockout were
induced by feeding a diet containing tamoxifen (1 g/kg diet) for 4 days.
Mice were returned to regular chow for an additional 4 days then eutha-
nized and livers were excised for subsequent studies. Themicewere on a
mixed SvJ129/FVB background and used at 8–10 weeks of age. All mice
were given food and water ad libitum and housed in a light- and
temperature-controlled facility. All animal studies were performed in
accordancewith the guidelines and approval of the National Cancer Insti-
tute, National Institutes of Health, Animal Care and Use Committee.
2.3. siRNA interference
Cells were transfected with equal amounts of small interfering RNA
(siRNA) oligonucleotides against GFP (5′-GGC UAC GUC CAG GAG CGC
ACC-3′), as control, or against HNF4α (ON-TARGET plus SMART pool
siRNAs J-065463-05/06/07/08, Dharmacon, Lafayette, CO) or against
DNMT3A (ON-TARGET plus SMART pool siRNAs J-065433-09/10/11/
12, Dharmacon, Lafayette, CO) and DNMT3B (ON-TARGET plus SMART
B0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
siGFP siHNF4
m
R
N
As
 r
el
at
iv
e 
ex
pr
es
si
on
DNMT3A
***
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
siGFP siHNF4
m
R
N
As
 r
el
at
iv
e
ex
pr
es
si
on
DNMT3B
*
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
siGFP siHNF4
m
R
N
As
 r
el
at
iv
e 
ex
pr
es
si
on
DNMT1
ns
DNMT3B
CDK4
si
G
FP
s
iH
N
F4
DNMT3A
CDK4
si
G
FP
s
iH
N
F4
si
G
FP
si
HN
F4
DNMT1
CDK4
0
0,5
1
1,5
2
Pr
ot
ei
n
s 
re
la
tiv
e
ex
pr
es
si
o
n
DNMT3A
***
0
0,5
1
1,5
2
Pr
ot
ei
n
s 
 
re
la
tiv
e
ex
pr
es
si
o
n
DNMT1
ns
0
0,5
1
1,5
2
Pr
ot
ei
n
s 
 
re
la
tiv
e
ex
pr
es
si
o
n
DNMT3B
**
A
0
0,5
1
1,5
2
2,5
3
3,5
4
m
R
N
As
 r
el
at
iv
e 
ex
pr
es
si
on
siGFP
siHNF4
*** ***
*
*
HNF4
CDK4
si
G
FP
si
HN
F4
0
0,5
1
1,5
Pr
ot
ei
ns
re
la
tiv
e
ex
pr
es
si
o
n
HNF4
*
HNF4 Snail Mmp9 Occludin
Fig. 1. HNF4α silencing induces DNMT3A and DNMT3B in hepatocytes. (A) Left panel: RT-qPCR analysis for the indicated genes in HNF4α silenced (for 48 h) (siHNF4α), compared to
control siGFP cells. The values are calculated by ΔΔCt method and expressed as relative versus the control (arbitrary value = 1). Right panel: Western blot and densitometric analysis
on total protein extracts from siHNF4α and siGFP cells. WB figures represent one indicative experiment of three independent ones. Densitrometic values of protein amounts normalized
by immunoblotting for CDK4 are expressed as fold of expression vs the control (siGFP). Statistically significant differences are reported (*p b 0.05, ***p b 0.001) for three independent ex-
periments. RT-qPCR (upper panels) andWestern blot (middle panels) analysis for the indicatedmarkers in siHNF4α and siGFP cells. Densitometric analysis (lower panels) and statistically
significant differences (*p b 0.05, **p b 0.01, ***p b 0.001; n.s. no significance) for three independent experiments are reported. Protein amount was normalized by immunoblotting for
CDK4 andWB figures represent one indicative experiment of three independent ones. (B) Western blot analysis for the indicatedmarkers on protein extracts from 6 hepatocyte-specific
Hnf4α knockout (KO)mice (Hnf4aF/F;AlbERT2cre; PMID: 22241473) and 6matched Cre negative littermates (Hnf4a+/+). Protein amount was normalized by immunoblotting forα-β actin, as
indicated. Densitometric analysis and statistically significant differences (**p b 0.01; ***p b 0.001; n.s. no significance) are reported.
921C. Cicchini et al. / Biochimica et Biophysica Acta 1849 (2015) 919–929pool siRNAs J-044164-05/06/07/08, Dharmacon, Lafayette, CO) by Lipo-
fectamine 2000 (Invitrogen, San Diego, CA, USA) according to commer-
cial protocol. Samples have been collected 48 h after transfection and
analyzed for transcripts and/or proteins levels.
2.4. Transfection of miR precursors and inhibitor treatment
miRs-29a and 29b knock down and miR-29b overexpression
were obtained respectively by the use of specific commercial
anti-miR inhibitors and a pre-miR precursor oligonucleotide, or thecorresponding amount of negative controls, purchased by Ambion®
(AM17110, AM17010, AM12499, AM10103 and PM10103, Life
Technology, Monza, Italy). Transfections were performed by Lipofec-
tamine 2000 (Invitrogen, San Diego, CA) according to commercial
protocol and analysis performed after 48 h. Cells were transfected
with a pool of anti-miR-29a and anti-miR-29b, or the corresponding
negative control, and interfered after 24 h by control siRNAs (siGFP)
or siRNAs specific for DNMT3A and DNMT3B (siDNMT3s). Samples
were collected and molecular analysis performed after the successive
48 h.
Hnf4 +/+ Hnf4 F/F;AlbERT2cre
1      2       3       4       5      6 
HNF4
- -ACTIN
- -ACTIN
- -ACTIN
- -ACTIN
DNMT1
DNMT3A
DNMT3B
1      2       3       4       5      6 
0
0,2
0,4
0,6
0,8
1
1,2
HNF4
***
Hnf4 +/+ Hnf4 F/F;AlbERT2cre
0
0,2
0,4
0,6
0,8
1
1,2
DNMT1
ns
Hnf4 +/+ Hnf4 F/F;AlbERT2cre
0
0,2
0,4
0,6
0,8
1
1,2
DNMT3B
**
Hnf4 +/+ Hnf4 F/F;AlbERT2cre
0
0,2
0,4
0,6
0,8
1
1,2
DNMT3A
Hnf4 +/+ Hnf4 F/F;AlbERT2cre
ns
Pr
ot
ei
n
s 
re
la
tiv
e 
ex
pr
es
si
on
Pr
ot
ei
n
s 
re
la
tiv
e 
ex
pr
es
si
on
Pr
ot
ei
n
s 
re
la
tiv
e 
ex
pr
es
si
o
n
Pr
ot
ei
n
s 
re
la
tiv
e 
ex
pr
es
si
o
n
C
Fig. 1 (continued).
922 C. Cicchini et al. / Biochimica et Biophysica Acta 1849 (2015) 919–9292.5. RNA extraction, reverse transcription (RT), reverse-transcription and
real-time polymerase chain reaction (RT–qPCR)
Total RNA was extracted by cell cultures and liver samples by TRIzol
(Invitrogen, Carlsbad, CA) or miRNeasy Mini Kit (QIAGEN GmbH, Hilden,
Germany) and reverse transcribed by iScriptTM c-DNA Synthesis Kit (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). FormiRs retrotranscription, the
cDNAwas obtained by reverse transcription of total RNA (200 ng), using
Superscript III reaction kit (Invitrogen, Carlsbad, CA, USA), and amplified
by qPCR reaction using GoTaq® qPCR Master Mix (Promega, Madison,
WI, USA). Relative amounts were obtainedwith 2−ΔΔCtmethod and nor-
malized toβ-actin, L34 or 18S (microRNAnormalized for U6 or Snord66).
Specific primers are listed in Table A.1.2.6. Western blot
Cells were lysed in RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM
NaCl, 1 mM EDTA, 100 mM NaF, 3 mMNa orthovanadate, 10% glycerol,
1% NP-40), supplemented with protease inhibitors (complete EDTA-
free, Roche Applied Science,MannheimGermany), and proteins quanti-
fied by Bradford protein assay reagent (Bio-Rad Laboratories, Hercules,
CA, USA). Equal amounts of proteins were separated by SDS-PAGE and
transferred onto nitrocellulose membrane (HybondTM ECLTM; GE
Healthcare, Freiburg Germany). Blots were blocked in 5% non-fat
milk prepared in TBST and incubated overnight at 4 °Cwith the primary
antibodies (antibodies α-HNF4α (C-19, sc-6556 1:500), α-CDK4 (C-22,
sc-260 1:1000), α-TUBULIN (TU-02, sc-8035 1:1000), α-DNMT3A
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Fig. 2. HNF4α controls the expression of miR-29a and miR-29b. (A) RT-qPCR analysis for
the indicatedmurinemicroRNAs on siHNF4α and siGFP cells as in Fig. 1. The values are cal-
culated by ΔΔCt method and expressed as relative versus the control (arbitrary value =
1). Statistically significant differences are reported (**p b 0.01) for three independent ex-
periments. (B) RT-qPCR analysis for the indicatedmiRs on liver samples from5hepatocyte
specific HNF4α KO mice (Hnf4α F/F;AlbERT2cre; PMID: 22241473) and 5 matched Cre nega-
tive littermates (Hnf4α+/+). Values are calculated byΔΔCtmethod and statistically signif-
icant differences are reported (*p b 0.05, ***p b 0.001). (C) qPCR analysis of ChIP assays
with an anti-HNF4α antibody, or normal rabbit IgG as negative control, on chromatin
from cells treated (TGFβ) or not (NT) with TGFβ for 24 h, showing the direct recruitment
of endogenous HNF4α on the miR-29a-b promoter. ChIP on specific HNF4α consensus
(miR-29 a–b) compared with non-specific genomic region (ns) are both normalized to
total chromatin input and expressed as (IP-NoAb), shown in dark bars, and (IgG-NoAb),
shown in white bars. Statistically significant differences are reported (**p b 0.01;
***p b 0.001; n.s. no significance) for three independent experiments.
923C. Cicchini et al. / Biochimica et Biophysica Acta 1849 (2015) 919–929(H-295, sc-20703 1:1000) and α-DNMT3B (H-230, sc-20704 1:1000)
were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnol-
ogy, CA, USA); α-Snail antibody (L70G2, 1:1000) from Cell Signaling
Technology® (Danvers, MA, USA)) and α-DNMT1 antibody
(60B1220.1, 1:1000) from Novus Biologicals (Littleton, CO, USA). Blots
were incubatedwith HRP-conjugated anti-Mouse and Rabbit secondary
antibodies (170-6516 and 172-1019, Bio-Rad Laboratories, Inc., Hercu-
les, CA, USA) or with HRP-conjugated anti-Goat IgG (705-036-147
1:5000, Jackson Immuno Research Laboratories, Inc., West Grove, PA,
USA) followed by enhanced chemiluminescence reaction (WESTAR
NOVA 2011 or ηC, Cyanagen, Bologna, Italy).
The impressed X-ray filmswere submitted to densitometric analysis
by using ImageJ open source software (release 1.44p, http://imagej.nih.
gov/ij). Values were expressed as specific protein signal/loading control
signals (TUBULIN or CDK4, as indicated) and reported as fold of
expression.
For liver samples, tissueswere lysed in RIPA buffer containing prote-
ase inhibitors using a Precellys 24 homogenizer. Lysateswere cleared by
centrifugation and protein concentrations quantified using Pierce BCA
Assay Kit (Thermo Scientific, Waltham, MA USA). Samples were ran
on pre-cast Criterion TGX gels and transferred to PVDF using TransBlot
Turbo transfer system (BioRad, Hercules, California, USA). Following
transfer, blots were processed as described above using primary
antibodies (α-HNF4α (H1415, PP-H1415-00 1:10K) from R&D Systems
(Minneapolis, MN, USA); α-DNMT3A (H-295, sc-20703 1:1000) and
α-DNMT3B (H-230, sc-20704 1:1000) from Santa Cruz Biotechnology;
α-DNMT1 antibody (60B1220.1, 1:1000) from Novus Biologicals
(Littleton, CO, USA) and α-β-actin (Ab8227 1:10K) from Abcam
(Cambridge, MA, USA)). Blots were incubated with HRP-conjugated
anti-Mouse (#7076, 1:5K) or anti-Rabbit (SC-7054) secondary antibod-
ies from Cell Signaling Technology and Santa Cruz Biotechnology,
respectively. Chemiluminescence detection was carried out using
Clarity Western ECL Substrate (BioRad) and a ChemDoc MP system
(BioRad).
2.7. Immunofluorescence analysis
For indirect immunofluorescence analysis, cells were fixed in 4%
paraformaldehyde and permeabilized with Triton-X100. The follow-
ing primary antibodies were used: anti-Snail rabbit polyclonal
(ab180714 Abcam Cambridge UK) 1/50, anti-MMP9 rabbit monoclo-
nal (ab1378867, Abcam Cambridge UK) 1/50, anti-Vimentin rabbit
monoclonal (ab92547, Abcam Cambridge UK) 1/400, and anti-E-
cadherin mouse monoclonal (BD 610182 BD Biosciences Pharmingen,
Palo Alto, CA, USA) 1/50. Secondary antibodies (anti-mouse Alexa-
Fluor 594, anti-rabbit Alexa-Fluor 488; 1/400) were from Molecular
Probes (Eugene, OR, USA). DNA has been stained by DAPI (Santa
Cruz Biotechnology, Inc., CA, USA). Preparations were examined
under Nikon Eclipse fluorescent microscope equipped with a 20×
(0.9 NA) and a CCD camera (Nikon Inc.). Digital images were proc-
essed with Adobe Photoshop 7 software (Adobe Systems, Mountain
View, CA). The same enhanced color levels were applied for the
green channel.
2.8. Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis was performed as previously reported [19] by using
5 μg rabbit anti-HNF4α (H-171, sc-8987; Santa Cruz Biotechnology,
Inc., CA, USA) or the negative control normal rabbit IgG (SC-2027;
Santa Cruz Biotechnology, Inc., CA, USA). 5 ng of immunoprecipitated
DNA and the relative controls were used as templates for real time
qPCR analysis, performed in triplicate. Primers are reported:HNF4α con-
sensus onmiR-29a-b promoter forward 5′-TTGTCGACTCTAACAGATCG-3′
and reverse 5′-GAGCACGAGGCTTACACATT-3′. Non-specific genomic
control region (TIMM17) forward 5′-ACGGATGTGGCCCTTCTGGCT-3′
and reverse 5′-CCGCTCCGAAACGCCCACAA-3′. ChIP analyses (by
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compared with non-specific genomic regions (ns), were both normal-
ized to total chromatin input and expressed as (IgG-NoAb) and
(IP-NoAb).2.9. Statistical analysis
Student's t test was used for statistical analyses. All the tests were
two-sided and a p-value b 0.05 was considered statistically significant
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cance was higher additional marks were added (p-value b 0.01 = **,
p-value b 0.001 = ***).2.10. Bioinformatic analysis
Regulatory sequence (up to 1 kb upstreamof transcription start site)
of murine microRNA-29a-b was obtained from ENSEMBL (http://www.
ensembl.org) and submitted to MatInspector Professional (release 8.0,
Genomatix, Munchen, Germany), using the vertebrate matrix library
and optimized thresholds, to identify putative HNF4α binding sites.3. Results
3.1. HNF4α impairment induces DNMT3A and DNMT3B expression
In order to identify a conceivable link between the master regulator
of MET, HNF4α, and epigenetic modifications, we first focused on the
DNA methylation machinery and analyzed DNMT1, DNMT3A and
DNMT3B expression in differentiated hepatocytes in which HNF4α
has been knocked-down. In these cells, the HNF4α interference by
siRNAs (Fig. 1A) was previously found sufficient to determine the loss
of the hepatocyte differentiated phenotype and the expression of sever-
al mesenchymal genes under the control of this transcriptional regula-
tor. In particular, HNF4α has been proven to act as a pivotal element
in maintaining a differentiated epithelial state by acting as a direct
repressor of Snail, Slug and HMG1, the main inducers of EMT [16].
Here, oncemonitored that HNF4α silencing induced both themaster
regulator Snail and the mesenchymal marker metalloprotease-9
(Mmp9) and caused the repression of the epithelial marker Occludin
(Fig. 1A; as expected according to [16]), we investigated on DNMTs: as
shown in Fig. 1B, in HNF4α interfered cells DNMT3A and DNMT3B,
but not DNMT1, were found up regulated at their transcript and protein
levels.
In extending our observations to an in vivomodel, hepatocyte-specific
Hnf4α knockout (KO) mice (Hnf4aF/F;AlbERT2cre; PMID: 22241473) and
matched Cre negative littermates (Hnf4aF/F) were analyzed for DNMT
expression. DNMT3B was significantly up regulated in all KO mice with
respect to littermates, while levels of DNMT1 andDNMT3Awere variable
within each group (Fig. 1C). DNMT3A up regulation was observed in half
of the animals examined, however, densitometry analysis did not
indicate statistical significance (Fig. 1C).
In particular, it is here worth recalling that hepatocytes fromHNF4α
KO mice were also previously shown to exhibit a marked induction of
Snail and of the mesenchymal proteins desmin, vimentin, and
a-smooth muscle actin, highlighting the requirement of HNF4α in
maintaining the hepatocyte epithelial identity [16].
Overall, these data provide evidence that the HNF4α impairment
in hepatocytes, previously reported to cause the acquisition by the
hepatocyte of mesenchymal traits [16], is sufficient to induce de
novo DNA methyltransferases DNMT3B (both in the cell culture and
in the animal models) and DNMT3A (only in the in vitro model)
up-regulation.Fig. 5.miR-29b overexpression interferes with TGFβ-mediated EMT. (A) Immunofluorescence a
for cells overexpressing a negative control microRNA precursor (Ctrl) or the same amount of a
staining shows nuclei (DNA). (B) RT-qPCR analysis for the indicated genes on cells in the same co
are expressed asmean± SD of triplicate samples. Statistically significant differences are reporte
analysis for the indicatedmarkers of total protein extracts from cells in the same conditions as ab
Figures represent one indicative experiment of three independent ones. Densitometric analysis
independent experiments are reported. (D)Western blot analysis and densitometric analysis fo
inhibitor (antimiRs NC) or a pool of bothmiR-29a andmiR-29b inhibitors (antimiRs 29ab) and
was normalized by immunoblotting for CDK4 or tubulin, as indicated. Figures represent
(*p b 0.05,**p b 0.01; n.s. no significance) for three independent experiments are reported.3.2.MicroRNA-29a and 29b, targetingDNMT3A andDNMT3B, are regulated
by HNF4α
Previous studies demonstrated that miR-29 family members
efficiently target DNMT3A and DNMT3B transcripts in different cell
systems [17]. Another study revealed that miR-29a-mediated regula-
tion of DNMT is involved in TGFβ-induced EMT of transformed cells
[20]. In order to gain insight into a possible mechanism of DNMT3
isoform modulation by HNF4α, we investigated microRNA-29a and
microRNA-29b expression in HNF4α-interfered hepatocytes. As
shown in Fig. 2A and B, miR-29a and miR-29b were both found
expressed in differentiated hepatocytes and, notably, highly correlating
to HNF4α expression; HNF4α silencing in cells, in fact, caused a strong
decrease of their levels, while in in vivo knockout a marked decrease
was observed for miR-29b only. Finally, since our bioinformatic analysis
viaMatInspector revealed putative HNF4α binding sites on themiR-29a
and miR-29b shared promoter, we investigated the possible direct
control of miR-29s expression by this master regulator. Chromatin
immunoprecipitation (ChIP) analysis (Fig. 2C) showed the direct
recruitment of endogenousHNF4α on themiR-29a-b promoter in hepa-
tocytes, in which miRs-29 are expressed, and its displacement during
EMT, when its activity is impaired by TGFβ and miRs-29 are repressed
[21,16]. Overall, our results suggest that HNF4α is directly involved in
the induction of miR-29a and -29b expression, thus impairing de novo
DNA methylation in differentiated hepatocytes.3.3. DNMT3A and DNMT3B are required in TGFβ-induced EMT
Data so far illustrated and obtained in differentiated hepatocytes
may be interpreted as amechanism that antagonizes epigenetic modifi-
cations and stabilizes the hepatocyte epithelial phenotype. In order to
investigate the functional requirement for a de novo DNA methylation
in the dynamic of hepatocyte EMT, we analyzed DNMT3 expression
during the transition.
As shown in Fig. 3 (and in line with a previous report [19]), tgfβ
treatment induced an EMT, as judged by immunofluorescence analysis
of mesenchymal (i.e. Snail, MMP9, Vimentin) and epithelial (E-
cadherin) markers (Fig. 3A); notably, in these conditions an inverse
correlation between mir-29a and mir-29b expression and DNMT3A
and DNMT3B (but not DNMT1), at both transcriptional and protein
levels, was observed (Fig. 3B–C–D). In order to evaluate whether the
de novo DNA methyltransferase modulation in tgfβ-induced EMT was
only correlative or rather causal to the transition, we analyzed the ef-
fects of its inhibition. To this aim, cells were treated with the inhibitor
5-Azacytidine (5-Aza), a nucleotide analog that is incorporated into
DNA, where it produces an irreversible inactivation of DNA methyl-
transferases [22]. As shown in Fig. 4A, immunofluorescence analysis in
control tgfβ-treated hepatocytes highlighted i) acquisition of a fibro-
blastic phenotype with MMP9 induction, ii) Snail nuclear staining and
iii) E-cadherin delocalization and down regulation. Conversely, cells
co-treated with tgfβ and 5-Aza still retained an epithelial morphology
with membrane staining of E-cadherin. Coherently, quantitative
qrt-PCR analysis showed that tgfβ treatment of 5-Aza-treated cells did
not cause a significant Snail induction and, consequently, did not causenalysis for the indicated epithelial (E-cadherin) andmesenchymal (Snail, MMP9)markers
pre-miR-29b and either treated or not with TGFβ for 24 h (magnification ×20). Blue DAPI
nditions as above. The values are calculated byΔΔCtmethod and expressed as above. Data
d (*p b 0.05, **p b 0.01, ***p b 0.001) for three independent experiments. (C)Western blot
ove. Protein amountwas normalized by immunoblotting for CDK4or tubulin, as indicated.
and statistically significant differences (*p b 0.05, **p b 0.01, n.s. no significance) for three
r the indicatedmarkers on cells transiently transfectedwith the negative controlmicroRNA
silenced for both DNMT3A and B (siDNMT3s) or as control for GFP (siGFP). Protein amount
one indicative of three independent experiments. Statistically significant differences
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(Fig. 4B).
Finally, we aimed to clarify whether ectopic expression of mir-29
impacts EMT. Notably, as shown in Fig. 5A–B–C, the overexpression of
a mir-29b precursor in hepatocytes undergoing tgfβ-induced EMT im-
peded the acquisition of the mesenchymal phenotype (i.e. induction
of Snail and MMP9 and downregulation/delocalization of E-cadherin)
and this was paralleled by the interference with DNMT3s and Snail up
regulation.
Moreover, we analyzed the effects of endogenous mir-29a and
mir-29b knock down. In cells treated with a pool of specific mir-29a
and mir-29b inhibitors (antimirs 29ab), DNMT3s proteins were found
positively modulated and this effect was counteracted by DNMT3A
and B silencing (Fig. 5D). It's worth noting that, since the DNMT3A
simultaneous interference induces, per se, higher DNMT3B levels
(Fig. 5D and data not shown), the DNMT3B silencing in the presence
of control anti-mir is not detectable.
With respect to the transition, mir-29 a and mir-29b inhibitors
treatment induced the expression of the EMT master regulator Snail;
notably, this effect was opposed by DNMT3s silencing (Fig. 5D);
transcript levels of others EMT markers (e.g. MMP9, Vimentin and
E-Cadherin) were found not significantly affected (data not shown).
Overall these results suggest a functional role for DNMT3s in the
upregulation of EMT master factor Snail thus suggesting the need for
DNMT3s repression in differentiated cells; presented data also indicate
HNF4α as a conceivable executor of this repressive role through the
regulation of miRNAs-29 targeting DNMT3s.
4. Discussion
In the current study, we provide evidence for a molecular mecha-
nism functionally linking a master regulator of EMT/MET dynamic,
namely HNF4α, to the epigenetic modifications featured by de novo
DNA methylation.
Molecularmechanisms triggering and controlling EMT/MET dynam-
ics have been so far only partially unveiled. In particular, themain effort
has been dedicated to the identification of transcriptional regulators;
the EMT main effectors have been indeed identified in transcriptional
repressors (i.e. Snail, Slug, ZEB) targeting several epithelial genes [23];
conversely, a few master factors have been functionally linked to the
MET acting by the down regulation of EMT-inducing repressors and
restoring tissue-specific epithelial identities.
Although the EMT/MET profound gene reprogramming conceivably
implies an equally deep remodeling of epigenetic setting, only recent
reports inform on key roles for epigenetic code modifications also in
these transitions [24–27]. Moreover, the possibility that master effec-
tors of EMT andMETmight directly impact the epigenetic modifications
underlying these complex phenomena is still largely unexplored. Here,
we extend the “to date” unveiled HNF4α activities to the capacity to
influence epigenetic modifications performed by DNMT3s.
The liver-enriched transcriptional factor HNF4α is a well-known
master factor of MET [13,28–31] initially characterized as a positive
regulator of transcription of epithelial genes and recently reported to
act also as a direct repressor of mesenchymal genes and master EMT-
regulators [16]. Herein, using both cell culture and liver-specific Hnf4α
knockoutmousemodels,we demonstrated a direct correlation between
loss of HNF4α and up-regulation of DNMT3B, which supports a func-
tional role during Hnf4a-mediated epigenetic remodeling. With respect
to DNMT3A, in vivo data indicated up regulation in only half of the
animals analyzed and we consider the data to have a statistical value
only for the cellular model.
Notably, HNF4α impairment causes the negative regulation of miR-
29a and miR-29b, targeting DNA methyltransferase transcripts.
Concerning mechanisms, we provided evidence for HNF4α binding to
miR-29a and miR-29b common promoter thus suggesting as HNF4α
could regulate DNMT3A and DNMT3B abundance in hepatocytesthrough miRs-29 regulation; further experiments are required to sup-
port the here suggested central and direct role of HNF4α. Our evidence
for a miRNA-mediated control of EMT/MET dynamics are in line with
previous evidence regarding miR-34/Snail/HNF4α and the miR-200/
Snail/Zeb circuits [32,33], thus highlighting a key role for miRNAs in
the fine tuning of gene expression that guarantees cellular plasticity.
Further studies are required to clarify whether the here proposed
post-transcriptional mechanism of miRs-29 regulation by HNF4α is
paralleled by an HNF4α-mediated DNMT3s transcriptional control.
Finally, we have shown that the rearrangement of DNAmethylation
pattern is required to fulfill EMT: treatment with 5-Azacytidine inhibi-
tor, indeed, impeded the acquisition of the mesenchymal phenotype
by TGFβ-treated hepatocytes, consistent with the observation that
Snail was not induced and, coherently, E-cadherin was still retained at
the membrane. Notably, miR-29b precursor overexpression interfered
with the TGFβ-induced Snail up regulation and with the loss of epithe-
lial phenotype. Conversely, treatment with both miR-29a and -29b spe-
cific inhibitors caused Snail induction and, of note, this effect is impaired
by DNMT3 silencing. This demonstrates the significance of themiRs-29-
DNMT3mechanism in controlling EMT. Interestingly, a recent report by
Parpart and colleagues [34] correlated low levels of miR-29 and
DNMT3A induction to aggressiveness of HCCs. This is in linewith the ob-
servations by Kogure et al [20], showing the involvement of miR-29a in
DNMT control in HCC cells. Further studies will be necessary to evaluate
a possible direct role of miRs-29 in Snail regulation.
5. Conclusions
In conclusion, from our data it emerges the functional role for
DNMTs in the execution of the EMT thus highlighting the need for
their repression in differentiated cells.
Our results suggest also the HNF4α-miRNAs-29 axis as a possible
mediator of this repression; thus the negative control of de novo DNA
methylation activities could be included among the HNF4α-mediated
effects conferring histo-specificity.
Further understanding of the mechanism by which HNF4α impairs
epigenetic remodeling mediated by DNA methylation will hopefully
be instrumental for further research on reprogramming and ultimately
for cell therapies in late stages of hepatocyte tumorigenesis.
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